22Oct 2023
Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma

Chemotherapy and Immune Checkpoint Blockade for Gastric and Gastroesophageal Junction Adenocarcinoma

Combining immune checkpoint blockade (ICB) with chemotherapy has shown improved outcomes in patients with metastatic gastric and gastroesophageal junction (G/GEJ) adenocarcinoma. However, the efficacy of this combination in the perioperative setting was unknown. This phase 2 nonrandomized controlled trial aimed to evaluate the safety and preliminary activity of perioperative chemotherapy and ICB followed by maintenance ICB in resectable G/GEJ adenocarcinoma. Of the 34 evaluable patients, 20.6% achieved a pathologic complete response, and 17.6% achieved a pathologic near-complete response. Disease-free survival (DFS) and overall survival (OS) were encouraging, with 2-year rates of 67.8% and 80.6%, respectively. The treatment was well tolerated, with manageable adverse events. These results highlight the potential of checkpoint inhibition in combination with perioperative chemotherapy for locally advanced G/GEJ adenocarcinoma.

  • #gastroenterology

Like

Save

Share